Table 1.

Used human serum samples in this study

		n (female/male)	Mean age (range)	Time point of sampling
Patients	Severe symptoms, hospitalized (ICU), unvaccinated	27 (7/20)	65 (39–86)	7–25 days after symptom onset (mean 12 days)
Vaccinated persons	2×BNT162b2 (Corminaty, BioNTech-Pfizer)	69 (40/29)	42 (23–66)	7–54 days after 2nd dose (mean 22 days)
	2×mRNA-1273 (Spikevax, Moderna)	6 (2 /4)	38 (19–70)	5–55 days after 2nd dose (mean 26 days)
	1×Ad26.COV2.S (Janssen COVID-19 vaccine, Johnson&Johnson)	6 (2/4)	35 (24–40)	14–33 days after 1st dose (mean 26 days)
	2× BNT162b2 or 1×Ad26.COV2.S boosted by 1× BNT162b2 (or mRNA-1273)	34 (20/14)	39 (24–66)	5–49 days after 3rd/2nd dose (mean 19 days)